<DOC>
	<DOCNO>NCT00056654</DOCNO>
	<brief_summary>The primary purpose study determine new sustained-release 45 mg ( depot ) formulation leuprolide acetate reduce serum testosterone level maintain medically castrate level subject prostatic adenocarcinoma .</brief_summary>
	<brief_title>Study 6-Month Sustained-Release Formulation Leuprolide Acetate Prostate Cancer</brief_title>
	<detailed_description>The primary purpose study determine new sustained-release 45 mg ( depot ) formulation leuprolide acetate administer every 26 week 1 year , low testosterone level maintain medically castrate level subject prostatic adenocarcinoma . This study also evaluate pharmacokinetic profile 45 mg formulation ass safety formulation .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Histological diagnosis prostate cancer Need androgen deprivation treatment 1 year Serum testosterone level â‰¥ 150 ng/dL Life expectancy least 18 month ECOG Performance status grade 0,1 2 Hypersensitivity leuprolide acetate polylactic acid History bilateral orchiectomy , adrenalectomy , hypophysectomy History hypogonadism</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Leuprolide</keyword>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Prostate-specific Antigen</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>luprolide acetate</keyword>
</DOC>